T
The Community Research of South Florida | Hialeah, FL
Research site
(Unclaimed)
Site insights
Top conditions
Top treatments
Dapagliflozin
BMS-512148
Lebrikizumab
CS02
Diclofenac Sodium Gel
Naproxen
Upadacitinib
Metformin
BLU-5937
MHAA4549A
Curious how this site stacks up to its peers?
Data sourced from clinicaltrials.gov
Work at this site?
CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.
Active trials
2 of 16 total trials
This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of BLU-5937 in participants with Refractory Chronic Cough (RCC).
Enrolling
Refractory Chronic Cough
Drug: BLU-5937
Drug: Placebo
This is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis. It will last up to 33 months.
Active, not recruiting
Atopic Dermatitis
Biological: Lebrikizumab
Trial sponsors
B
C
I
Clinical trials
Research sites
Resources
Legal
© Copyright 2024 Veeva Systems